Rapamycin triggers FOXO‑dependent mitochondrial peptide release to mimic scarcity and extend lifespan

Hypothesis

Chronic mTORC1 inhibition by rapamycin extends lifespan not by repairing damage but by activating a mitochondrial retrograde signal—specifically the release of humanin and SHLPs—that engages FOXO transcription factors to enact a conserved famine‑response program. This peptide‑mediated stress response is both necessary and sufficient for the longevity benefit, and its efficacy depends on age‑related changes in mitochondrial sensitivity to mTORC1 activity.

Mechanistic Model

• Rapamycin inhibits mTORC1, lowering cytosolic ATP consumption and increasing the AMP/ATP ratio.
• The energy shift stimulates mitochondrial unfolded‑protein response (UPRmt) and raises mitochondrial membrane potential fluctuations, prompting the export of MDPs such as humanin and SHLP2 via a yet‑uncharacterized vesicle‑mediated route.
• Extracellular humanin binds a putative G‑protein‑coupled receptor on the same or neighboring cells, activating a cAMP‑PKA cascade that phosphorylates and inhibits Akt, thereby relieving FOXO repression.
• Nuclear FOXO transcription drives expression of autophagy genes, antioxidant enzymes, and additional MDPs, creating a positive feedback loop that sustains a low‑insulin/IGF‑1‑like state.
• Because mitochondrial sensitivity to mTORC1 rises with age (due to accumulated NAD+ decline and altered cardiolipin composition), the peptide surge is stronger in older animals, matching the observed age‑restricted efficacy of rapamycin.

Predictions & Tests

1. Rapamycin treatment should increase circulating humanin/SHLP levels in vivo. Measure plasma peptides by ELISA or mass spectrometry in young vs. old mice treated with rapamycin vs. vehicle; expect a significant rise only in older cohorts.
2. Genetic blockade of MDP secretion will abolish rapamycin‑induced lifespan extension. Use muscle‑specific knockout of the mitochondrial peptide export factor (e.g., VIPAS39 homolog) and compare survival curves of rapamycin‑treated knockouts to controls; predict no lifespan benefit.
3. FOXO activation is downstream of MDP signaling. Treat FOXO‑deficient worms or mice with exogenous humanin; if lifespan extension requires FOXO, the peptide will fail to prolong life in the absence of FOXO.
4. Artificial MDP supplementation should mimic rapamycin’s effects in young animals. Inject recombinant humanin into young mice; anticipate improved healthspan markers (e.g., glucose tolerance, grip strength) without altering mTORC1 phosphorylation, indicating that the peptide can bypass the need for mTOR inhibition.
5. Circadian gating of MDP release. Sample mitochondria‑derived peptides at different zeitgeber times in calorie‑restricted and rapamycin‑treated animals; expect peak secretion during the active phase, linking the response to circadian regulation of mTORC1.

Potential Caveats

• Compensatory pathways may mask phenotypes in whole‑body knockouts; tissue‑specific rescues may be needed.
• Humanin assays suffer from antibody variability; orthogonal verification (e.g., targeted proteomics) is essential.
• The postulated MDP export mechanism remains hypothetical; uncovering it will require mitochondrial fractionation and secretion assays.

If these experiments confirm the predicted peptide surge and its dependence on FOXO, the hypothesis shifts the narrative from "damage repair" to "stress‑signal impersonation" as the core mechanism by which mTOR inhibition produces longevity.